PTSD
PTSD screening by GIA®, powered by digitalhumanOS™, uses Voice AI, Computer Vision, and Speech Biomarkers to detect ptsd through a single patient conversation. Screening performance: AUC 0.907. Screening takes 40 seconds with results in under 2 minutes.
Unaddressed trauma casts a long shadow, hindering healing and straining resources.
PTSD often goes unnoticed in post-acute care, delaying recovery and increasing the risk of complications. Our screening identifies at-risk patients, enabling targeted support and improved outcomes.
Key Facts
- Screening Time
- 40 seconds
- Results
- under 2 minutes
- Modalities
- Voice + Vision + Speech
- Validation
- Peer-Reviewed (19 studies)
- Status
- Live
This content is intended for informational purposes and does not constitute medical advice. Editorially reviewed by David Kaiser, CEO of Scienza Health, for accuracy in post-acute care operations.
About PTSD screening.
What data points are used to identify PTSD risk?
The AI analyzes vocal patterns, speech characteristics, and facial expressions associated with trauma and anxiety.
Is the PTSD screening process HIPAA compliant?
Yes, all data is processed and stored in accordance with HIPAA regulations, ensuring patient privacy and security.
How can early PTSD identification improve patient care?
Early identification allows for timely therapeutic interventions, reducing the long-term impact of trauma and improving overall patient well-being.
The science behind PTSD screening.
A 2005 study of PTSD prevalence in Veterans Affairs primary care (Magruder et al., General Hospital Psychiatry) found that providers identified only 46.5% of patients diagnosed with PTSD by structured clinical interview — fewer than half. Of identified patients, 47.7% had used mental health specialty services.
Prevalence of Posttraumatic Stress Disorder in Veterans Affairs Primary Care Clinics — General Hospital Psychiatry (2005-05)DOI: 10.1016/j.genhosppsych.2004.11.001 →Internal model performance report (v0.2.0, May 2026) from a confidential strategic clinical-validation partner. Reported AUC values (with sensitivity and specificity): depression 0.874 (Sens 0.722, Spec 0.866); anxiety 0.884 (Sens 0.764, Spec 0.850); PTSD 0.907 (Sens 0.888, Spec 0.745); acute stress and nervousness 0.910 (Sens 0.780, Spec 0.891); psychoactive substance use 0.845 (Sens 0.718, Spec 0.806); fatigue and malaise 0.827 (Sens 0.734, Spec 0.910); ADHD 0.848 (Sens 0.634, Spec 0.868); sleep disorders 0.823 (Sens 0.661, Spec 0.831); bipolar disorder 0.726 (Sens 0.444, Spec 0.860). Partner identity withheld per partnership agreement. Operator-confirmed 2026-05-21.
Internal multi-condition model performance report (v0.2.0) (2026-05)View all peer-reviewed research. See how GIA® screens for PTSD across care settings.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.